Arvinas and Pfizer Breast Cancer Trial Shows Promising Results
Company Announcements

Arvinas and Pfizer Breast Cancer Trial Shows Promising Results

Arvinas Holding Company (ARVN) has issued an announcement.

Arvinas, Inc. and Pfizer have revealed promising results from their Phase 1b trial of vepdegestrant combined with palbociclib (IBRANCE®) in treating ER+/HER2- breast cancer in patients with multiple prior lines of therapy. The latest follow-up data, consistent with earlier findings, showed a high clinical benefit rate and an overall response rate, with a median progression-free survival of over 11 months, which extended to nearly 14 months at the recommended Phase 3 dose. These outcomes, presented at the 2024 ESMO Breast Cancer Annual Congress, coupled with a manageable safety profile, indicate the potential of this treatment regimen in heavily pre-treated breast cancer patients.

See more insights into ARVN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyArvinas price target lowered to $40 from $50 at Oppenheimer
TipRanks Auto-Generated NewsdeskArvinas Reports Progress in Q3 2024 Financials and Trials
TheFlyArvinas price target lowered to $40 from $50 at Oppenheimer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App